Disclaimer: This site aggregates publicly available data from official government sources (FDA, ClinicalTrials.gov, PubMed, SEC EDGAR, NMPA) for general reference only. It does NOT constitute medical advice, diagnosis, treatment recommendations, or investment advice.

Clinical Trial

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions

NCT: NCT03603808 · COMPLETED

NCT IDNCT03603808
StatusCOMPLETED
Start Date2018-09-21
Completion2025-06-17

Brief Summary

This phase II trial studies the use of human papillomavirus (HPV) deoxyribonucleic acid (DNA) plasmids therapeutic vaccine VGX-3100 (VGX-3100) and electroporation in treating patients with human immunodeficiency virus (HIV)-positive high-grade anal lesions. Vaccines made from DNA may help the body build an effective immune response to kill tumor cells. Electroporation helps pores in your body's cells take in the drug to strengthen your immune system's response. Giving VGX-3100 and electroporation together may work better in treating patients with high-grade anal lesions.

Frequently Asked Questions

What is VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions?

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions is a clinical trial registered under NCT03603808. Current status: COMPLETED.

What is the status of NCT03603808?

The current status of NCT03603808 (VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions) is: COMPLETED.

When did VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions start?

VGX-3100 and Electroporation in Treating Patients With HIV-Positive High-Grade Anal Lesions started on 2018-09-21.

Official Source

View on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov API. For the most current status, refer to the official record.

↑